CASP8 and cancer: In the same work, in vivo experiments demonstrated thatthe 6N deletion variant was associated with lower apoptoticreactivity of T-lymphocytes when stimulated by cancer cells.Based on this, the identified CX3CR1*G/A+CASP8*I/I variantmay be associated with increased apoptotic activity anddestabilization of the atherosclerotic plaque.